Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib with or without pembrolizumab in first-line KRAS G12C-mutated advanced non-small cell lung cancer
NL-OMON60564Phase 3Recruiting
- Sponsor
- Mirati Therapeutics
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adagrasib and pembrolizumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Mirati Therapeutics. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60564.